Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
5
VBIZF Quote, Financials, Valuation and Earnings
Last price:
$0.1900
Seasonality move
:
3194.18%
Day range:
$0.1939 - $0.1939
52-week range:
$0.0709 - $0.4294
Dividend yield:
0%
P/E ratio:
19.39x
P/S ratio:
1.78x
P/B ratio:
0.76x
Volume:
--
Avg. volume:
86
1-year change:
173.48%
Market cap:
$409.1M
Revenue:
$276M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$126.3M | -$0.43 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
$0.1939 | -- | $409.1M | 19.39x | $0.00 | 0% | 1.78x |
|
ADAG
Adagene, Inc.
|
$1.89 | $9.22 | $89M | -- | $0.00 | 0% | 850.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.85 | $4.00 | $17.5M | -- | $0.00 | 0% | 0.50x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.21 | -- | $3.9M | -- | $0.00 | 0% | 0.97x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.64 | $49.17 | $2B | -- | $0.00 | 0% | 4.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
24.82% | -7.636 | -- | 1.26x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.358 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.497 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.111 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 6.279 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.105 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Viva Biotech Holdings vs. Competitors
-
Which has Higher Returns VBIZF or ADAG?
Adagene, Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of --. Viva Biotech Holdings's return on equity of -1.8% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About VBIZF or ADAG?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 388.06%. Given that Adagene, Inc. has higher upside potential than Viva Biotech Holdings, analysts believe Adagene, Inc. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 ADAGAdagene, Inc.6 2 0 -
Is VBIZF or ADAG More Risky?
Viva Biotech Holdings has a beta of 0.525, which suggesting that the stock is 47.48% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VBIZF or ADAG?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or ADAG?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Viva Biotech Holdings's net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 1.78x versus 850.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings1.78x 19.39x -- -- ADAGAdagene, Inc.850.60x -- -- --
-
Which has Higher Returns VBIZF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of -353.92%. Viva Biotech Holdings's return on equity of -1.8% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About VBIZF or CASI?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 370.59%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Viva Biotech Holdings, analysts believe CASI Pharmaceuticals, Inc. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is VBIZF or CASI More Risky?
Viva Biotech Holdings has a beta of 0.525, which suggesting that the stock is 47.48% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.505%.
-
Which is a Better Dividend Stock VBIZF or CASI?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or CASI?
Viva Biotech Holdings quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Viva Biotech Holdings's net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 1.78x versus 0.50x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings1.78x 19.39x -- -- CASICASI Pharmaceuticals, Inc.0.50x -- $3.1M -$10.9M
-
Which has Higher Returns VBIZF or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of -86.16%. Viva Biotech Holdings's return on equity of -1.8% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About VBIZF or CPHI?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Viva Biotech Holdings has higher upside potential than China Pharma Holdings, Inc., analysts believe Viva Biotech Holdings is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is VBIZF or CPHI More Risky?
Viva Biotech Holdings has a beta of 0.525, which suggesting that the stock is 47.48% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.259%.
-
Which is a Better Dividend Stock VBIZF or CPHI?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or CPHI?
Viva Biotech Holdings quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Viva Biotech Holdings's net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 1.78x versus 0.97x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings1.78x 19.39x -- -- CPHIChina Pharma Holdings, Inc.0.97x -- $756.2K -$651.5K
-
Which has Higher Returns VBIZF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Viva Biotech Holdings's net margin of --. Viva Biotech Holdings's return on equity of -1.8% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About VBIZF or SVA?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Viva Biotech Holdings has higher upside potential than Sinovac Biotech Ltd., analysts believe Viva Biotech Holdings is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is VBIZF or SVA More Risky?
Viva Biotech Holdings has a beta of 0.525, which suggesting that the stock is 47.48% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.623%.
-
Which is a Better Dividend Stock VBIZF or SVA?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or SVA?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Viva Biotech Holdings's net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 1.78x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings1.78x 19.39x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns VBIZF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Viva Biotech Holdings's net margin of -30.98%. Viva Biotech Holdings's return on equity of -1.8% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About VBIZF or ZLAB?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 178.74%. Given that Zai Lab Ltd. has higher upside potential than Viva Biotech Holdings, analysts believe Zai Lab Ltd. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is VBIZF or ZLAB More Risky?
Viva Biotech Holdings has a beta of 0.525, which suggesting that the stock is 47.48% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.508%.
-
Which is a Better Dividend Stock VBIZF or ZLAB?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or ZLAB?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Viva Biotech Holdings's net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 1.78x versus 4.28x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings1.78x 19.39x -- -- ZLABZai Lab Ltd.4.28x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
